Lpath Withdraws From Pfizer's Process to Assign iSONEP Rights

        Lpath Withdraws From Pfizer's Process to Assign iSONEP Rights

PR Newswire

SAN DIEGO, Dec. 12, 2013

SAN DIEGO, Dec. 12, 2013 /PRNewswire/ --Lpath, Inc. (Nasdaq: LPTN), the
category leader in lipid-targeted therapeutics, is no longer actively
participating in Pfizer's process to assign the exclusive option it has for a
worldwide license to develop and commercialize Lpath's iSONEP™. Pfizer has
informed Lpath that its offers were not competitive with other offers.

Lpath's CEO, Scott Pancoast commented, "We made a serious effort to reacquire
this asset, and we continue to believe in iSONEP's prospects. However, given
our commitment to fiscal discipline and building shareholder value, we simply
are not in a position at this time to increase our offer. We appreciate the
competing interest shown in iSONEP by the other parties and look forward to
Pfizer's process coming to a successful close."

About Lpath
San Diego-based Lpath, Inc. (NASDAQ: LPTN), an antibody-platform company, is
the category leader in lipidomics-based therapeutics, an emerging field of
medicine that targets bioactive signaling lipids for treating a wide range of
human disease. Lpath's ImmuneY2™ drug-discovery engine has the unique ability
to generate therapeutic antibodies that bind to and inhibit bioactive lipids
that contribute to disease. The company has developed four drug candidates,
two of which—iSONEP™ for wet AMD and ASONEP™ for cancer—are currently being
investigated in Phase 2 trials. The other candidates are an anti-LPA antibody
that holds promise in neuropathic pain and neurotrauma and an anti-leukotriene
antibody that holds promise in respiratory disease. For more information,
visit www.Lpath.com.

About Forward-Looking Statements
The company cautions you that the statements included in this press release
that are not a description of historical facts are forward-looking statements.
These include statements regarding Pfizer's plans to divest its exclusive
option for a worldwide license to develop and commercialize iSONEP, third
party interest in acquiring the exclusive option from Pfizer, and Pfizer's
ability to successfully complete a sale of the exclusive option. Actual
results may differ materially from those set forth in this press release due
to the risks and uncertainties inherent in the Company's business, including,
without limitation: the results of the Company's preclinical studies and
clinical trials may not support further clinical development and/or the
commercialization of its drug candidates; the Company may not successfully
complete additional clinical trials for its product candidates on a timely
basis, or at all; the Company may fail to obtain required governmental
approvals for any its drug candidates; the Company may not be successful in
maintaining its commercial relationship with Pfizer Inc. or any third party
who acquires Pfizer's exclusive option to iSONEP; and the Company may not be
able to secure the funds necessary to support its preclinical-development and
clinical-development plans. More detailed information about the risk factors
and uncertainties that may affect the realization of forward-looking
statements is set forth in the Company's filings with the Securities and
Exchange Commission (the "SEC"), including its Annual Report on Form 10-K, its
Quarterly Reports on Form 10-Q, and its other filings with the SEC. These
documents may be read free of charge on the SEC's website at www.sec.gov. You
are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. All forward-looking statements are
qualified in their entirety by this cautionary statement, and the Company
undertakes no obligation to revise or update this press release to reflect
events or circumstances after the date hereof. This caution is made under the
safe harbor provisions of Section 21E of the Private Securities Litigation
Reform Act of 1995.

CONTACT:
Scott R. Pancoast
President and CEO
Lpath, Inc.
858-926-3200
spancoast@lpath.com
INVESTOR CONTACTS:
Westwicke Partners, LLC
Stefan Loren, Ph.D.     Robert H. Uhl
Managing Director       Managing Director
(443) 213-0507          (858) 356-5932
sloren@westwicke.com   robert.uhl@westwicke.com

SOURCE Lpath, Inc.

Website: http://www.lpath.com